Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Elicio Therapeutics (ELTX) Receivables - Other (2021)

Elicio Therapeutics filings provide 1 years of Receivables - Other readings, the most recent being $806000.0 for Q4 2021.

  • On a quarterly basis, Receivables - Other changed N/A to $806000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $806000.0, a N/A change, with the full-year FY2021 number at $806000.0, changed N/A from a year prior.
  • Receivables - Other hit $806000.0 in Q4 2021 for Elicio Therapeutics.
  • In the past five years, Receivables - Other ranged from a high of $806000.0 in Q4 2021 to a low of $806000.0 in Q4 2021.